23.05.2012 - British respiratory medicines company Prosonix Ltd. has extended its Series B financing round to £17.1m.
Oxford – The lion’s share of the new capital comes from new investor Gimv, a leading European technology investor, who contributed £5.7m. The rest was contributed by the syndicate of investors that participated in the first closing of the round in June 2011. The syndicate includes Ventech, Gilde Healthcare Partners, Entrepreneurs Fund, Quest for Growth and Solon Ventures.
The Oxford-based Prosonix announced it will use the proceeds of the financing to push forward its product pipeline of inhalable mono- and combination therapies. “These new funds will enable Prosonix to accelerate its activities aimed at attaining key performance and clinical data for our pipeline of excipient-free, drug-only respiratory medicines”, said David Hipkiss, Prosonix' CEO. His company works on development programs for an inhaled corticosteroid for asthma and a long-acting muscarinic antagonist for chronic obstructive pulmonary disorder. Its unique Multi-component Particle (MCP™) platform enables Prosonix to combine two or more drug molecules consistently in a pre-determined ratio in each and every particle in the formulation.
Karl Nägler, Venture Capital Partner at new investor Gimv, will join the Prosonix board as a Non-executive Director. „We are confident that Prosonix can become a significant player in the area of respiratory medicines“ said Nägler, stressing that Prosonix is at an important point in its development.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.